- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.08. | Enliven Therapeutics, Inc Q2 Loss Climbs | 1 | RTTNews | ||
| 13.08. | Enliven Therapeutics GAAP EPS of -$0.49 beats by $0.04 | 1 | Seeking Alpha | ||
| 13.08. | Enliven Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 13.08. | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update | 108 | PR Newswire | Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 47% with 32% of patients achieving MMR by 24 weeks... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 25.06. | Enliven Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.06. | TD Cowen bekräftigt Kaufempfehlung für Enliven Therapeutics-Aktie | 1 | Investing.com Deutsch | ||
| 20.06. | TD Cowen reiterates buy rating on Enliven Therapeutics stock | 1 | Investing.com | ||
| 16.06. | Goldman Sachs initiates Enliven Therapeutics stock with Buy rating | 1 | Investing.com | ||
| 13.06. | Enliven Therapeutics prices $200 million public offering | 1 | Investing.com | ||
| 13.06. | Enliven Therapeutics stock falls after pricing capital raise of $200M via securities offering | 1 | Seeking Alpha | ||
| 13.06. | Enliven Therapeutics announces $200 million public offering | 5 | Investing.com | ||
| 13.06. | Enliven Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.06. | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress | 266 | PR Newswire | Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent... ► Artikel lesen | |
| 30.05. | Mizuho erhöht Kursziel für Enliven Therapeutics-Aktie auf 41 US-Dollar | 1 | Investing.com Deutsch | ||
| 16.05. | BTIG raises Enliven Therapeutics stock target to $45 | 1 | Investing.com | ||
| 15.05. | Enliven Therapeutics GAAP EPS of -$0.57 beats by $0.01 | 1 | Seeking Alpha | ||
| 15.05. | Enliven Therapeutics stock target raised to $40 at H.C. Wainwright | 1 | Investing.com | ||
| 14.05. | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update | 329 | PR Newswire | Updated data from the Phase 1 ENABLE clinical trial of ELVN-001 in CML to be presented at the EHA 2025 Congress in June
EHA abstract reported cumulative MMR rate... ► Artikel lesen | |
| 14.05. | Enliven reports positive Phase 1 trial data for ELVN-001 in CML | 1 | Investing.com | ||
| 14.05. | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress | 311 | PR Newswire | Reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent... ► Artikel lesen |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 3,656 | +3,57 % | Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy | Original-Research: Valneva SE - von First Berlin Equity Research GmbH
29.08.2025 / 16:48 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den... ► Artikel lesen | |
| BIOFRONTERA | 2,540 | -1,93 % | PTA-Adhoc: Biofrontera AG: Biofrontera AG: Neue Prognose | DJ PTA-Adhoc: Biofrontera AG: Biofrontera AG: Neue Prognose
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR
Biofrontera AG: Biofrontera AG: Neue Prognose
Leverkusen (pta000/01.08.2025/12:00... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 44,600 | -1,33 % | 1 Reason Every Investor Should Know About CRISPR Therapeutics (CRSP) | ||
| AFFIMED | 0,972 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
| DENALI THERAPEUTICS | 13,380 | +0,83 % | Denali Therapeutics Inc.: Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights | Tividenofusp alfa BLA for Hunter syndrome accepted for priority review and assigned PDUFA target action date of January 5, 2026; company preparing for commercial launchDNL126 accelerated approval... ► Artikel lesen | |
| FATE THERAPEUTICS | 0,883 | -0,79 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates | First patient treated with FT819 off-the-shelf CAR T-cell product candidate following fludarabine-free conditioning for severe lupus nephritis demonstrated durability of response with drug-free definition... ► Artikel lesen | |
| CELLECTIS | 2,220 | +0,68 % | Cellectis Reports Second Quarter 2025 Financial Results & Business Updates | Cellectis to host an Investor R&D Day in New York City on October 16, 2025: Phase 1 dataset and late-stage development strategy for lasme-cel (UCART22) in r/r B-ALL to be presented End-of-Phase 1... ► Artikel lesen | |
| AGIOS | 33,000 | -2,37 % | Agios Pharmaceuticals, Inc.: Agios' PYRUKYND (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia | First regulatory approval for PYRUKYND in thalassemia, evaluated under SFDA's Breakthrough Medicines Program Agios partnered with NewBridge Pharmaceuticals, a regional specialty company focused on... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,114 | +1,10 % | Voyager Therapeutics, Inc. - 8-K, Current Report | ||
| UNIQURE | 14,030 | -4,00 % | uniQure Inc.: uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress | ~ Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to support a planned BLA submission in the first quarter of 2026;
~ Company expects to present AMT-130... ► Artikel lesen | |
| ENZO BIOCHEM | 0,388 | 0,00 % | Battery Ventures Completes Take-Private of Enzo Biochem | Apter joins as CEO to support the next stage of growth for the life-science reagents platform
BOSTON--(BUSINESS WIRE)--Battery Ventures, a global, technology-focused investment firm, announced the... ► Artikel lesen | |
| TECTONIC THERAPEUTIC | 16,650 | 0,00 % | Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025 | Data confirmed TX45's tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved... ► Artikel lesen | |
| SCILEX | 18,640 | 0,00 % | Scilex Holding Company (Nasdaq: SCLX) Announces Effectiveness of Registration Statement on Form S-4 for the Proposed Business Combination of Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc. | Denali's registration statement on Form S-4 declared effective by the Securities and Exchange CommissionExtraordinary general meeting of Denali Capital Acquisition Corp. shareholders to approve the... ► Artikel lesen | |
| ALLOGENE THERAPEUTICS | 1,120 | 0,00 % | Allogene Therapeutics, Inc.: Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation ... | Lymphodepletion Regimen Selection Made in Conjunction with the ALPHA3 Data and Safety Monitoring Board (DSMB) and Steering Committee, and in Consultation with the FDA Following an ALLO-647-Related... ► Artikel lesen | |
| NUVATION BIO | 2,945 | 0,00 % | Nuvation Bio To Present New Data on IBTROZI (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses | Presentations to include updated and additional Phase 2 clinical data for recently FDA-approved IBTROZI
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the... ► Artikel lesen |
ENLIVEN THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 20,890 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ENLIVEN THERAPEUTICS INC finden Sie auf Wallstreet Online.